On February 12, 2026, the U.S. Food and Drug Administration approved significant labeling changes for six menopausal hormone therapy products.

The FDA removed statements about cardiovascular disease, breast cancer, and probable dementia from the products’ boxed warnings, the agency’s most prominent type of drug safety warning. The update applies to products representing systemic estrogen, combined estrogen and progestogen, progesterone, and local vaginal estrogen therapy. 

This is an important shift in how the benefits and risks of menopause hormone therapy are communicated.

It does not mean hormone replacement therapy is risk-free. It does not mean every woman should take hormones. It also does not erase cardiovascular, clotting, breast cancer, or other safety considerations from every product label.

What it does mean is that menopause care is moving toward a more individualized view of risk based on a woman’s age, symptoms, health history, treatment type, route of administration, and time since menopause.

Key Takeaways

• The FDA approved updated labeling for six menopausal hormone therapy products in February 2026.
• References to cardiovascular disease, breast cancer, and probable dementia were removed from the boxed warnings.
• Cardiovascular and breast cancer safety information remains elsewhere in the prescribing information for systemic products.
• The boxed warning for endometrial cancer remains on systemic estrogen-only products.
• Updated systemic labels now emphasize whether treatment begins before age 60 or within 10 years of menopause.
• Local vaginal estrogen and systemic hormone therapy should not be treated as medically identical.
• The label changes do not replace personalized screening, prescribing, and follow-up.

What Did the FDA Change About Menopause Hormone Therapy?

Menopausal hormone therapy, also called MHT or hormone replacement therapy, uses estrogen, progestogens, or a combination of hormones to manage symptoms associated with declining ovarian hormone production.

According to the FDA, the updated labeling changes include several important revisions. 

Changes to the Boxed Warning

For menopausal hormone therapies included in the FDA’s labeling initiative, the agency requested the removal of boxed-warning language related to:

• Cardiovascular disease
• Breast cancer
• Probable dementia
• Endometrial cancer, except on systemic estrogen-only products

The FDA also removed the general boxed-warning recommendation that hormone therapy should always be used at the lowest effective dose for the shortest possible duration.

That language had often been interpreted as a universal rule rather than a starting point for individualized medical decision-making.

Treatment duration should now be based more clearly on symptoms, goals, clinical response, personal risk factors, and regular reassessment.

Changes Throughout the Full Prescribing Information

Removing a risk from a boxed warning does not necessarily remove every discussion of that risk from the medication’s full label.

For systemic hormone therapy products, the FDA’s requested changes include:

• Removing the probable dementia warning throughout the label
• Adding information about starting treatment before age 60 or within 10 years of menopause
• Adding Women’s Health Initiative data specific to women ages 50 to 59
• Retaining cardiovascular disease information
• Retaining breast cancer information
• Retaining the endometrial cancer boxed warning for systemic estrogen-only therapy

For local vaginal estrogen products, the FDA requested that safety information be condensed and focused more directly on risks relevant to local treatment.

This distinction matters. A low-dose vaginal estrogen product intended primarily for vaginal and urinary symptoms does not create the same systemic exposure as a standard oral or transdermal estrogen treatment.

Which Hormone Therapy Products Received Updated Labels?

The FDA’s first approved group includes six products across four menopausal hormone therapy categories. 

Systemic Estrogen and Progestogen

• Bijuva, containing estradiol and progesterone

Systemic Estrogen Alone

• Divigel
• Cenestin
• Enjuvia

Progestogen Alone

• Prometrium

Local Vaginal Estrogen

• Estring

This does not mean the labeling for every estrogen, progesterone, or combination product changed immediately on February 12, 2026.

The FDA reported that 29 drug companies had submitted proposed labeling changes. Additional product labels may be revised as those submissions complete the regulatory review process.

Patients should review the current prescribing information for their specific medication rather than assuming all products now carry identical language.

Why Did the FDA Reconsider the Boxed Warnings?

The original warnings were heavily influenced by results from the Women’s Health Initiative, or WHI, a group of large clinical trials launched in the 1990s.

The WHI evaluated whether hormone therapy could prevent chronic conditions such as heart disease, cancer, and fractures in postmenopausal women. The studies were not designed primarily to evaluate treatment for newly developing hot flashes, sleep disruption, or other symptoms during the early menopause transition.

The average participant was approximately 63 years old. Many participants were more than a decade beyond menopause when treatment began.

The trials also studied specific oral hormone regimens:

• Conjugated equine estrogen alone in women without a uterus
• Conjugated equine estrogen combined with medroxyprogesterone acetate in women with a uterus

Those findings were then used to shape warnings across a much broader range of hormone products, including different doses, formulations, delivery methods, and local vaginal products.

Over time, clinicians and researchers raised concerns about applying results from an older study population to younger, generally healthier women seeking treatment near the beginning of menopause.

The FDA’s updated Bijuva label now specifically acknowledges that the relevance of the original WHI findings to other doses, routes, and estrogen-progestogen products is not fully known. It also directs clinicians to consider initiating treatment in women younger than 60 or within 10 years of menopause onset. 

What Is the Menopause “Timing Window”?

The timing window refers to the period in which the balance between the benefits and risks of systemic hormone therapy may be most favorable.

For many healthy women experiencing bothersome symptoms, that window generally means:

• Younger than 60 years old
• Within 10 years of menopause onset

The Menopause Society has stated that the benefits of hormone therapy generally outweigh the risks for most healthy, symptomatic women who fall within this group. It also recommends evaluating risk based on age, time since menopause, dose, formulation, treatment duration, and route of administration. 

This does not create an automatic cutoff at age 60.

Some women may continue hormone therapy beyond age 60 or 65 for persistent symptoms, quality-of-life concerns, or osteoporosis prevention after an appropriate review of their risks and benefits.

However, starting systemic hormone therapy for the first time later in life may carry a different risk profile than beginning treatment closer to menopause.

What the FDA Update Does Not Mean

The labeling change is meaningful, but several misleading interpretations should be avoided.

It Does Not Mean Hormone Therapy Has No Risks

The updated labels continue to include contraindications, warnings, and precautions.

Depending on the medication, systemic hormone therapy may still require careful evaluation in women with:

• A history of breast cancer
• Known estrogen-dependent cancer
• Unexplained vaginal bleeding
• Active or previous deep vein thrombosis
• Pulmonary embolism
• Previous stroke or heart attack
• Known clotting disorders
• Active liver disease
• Certain cardiovascular risk factors

The precise contraindications differ by medication and should be reviewed using the current product label.

It Does Not Mean Breast Cancer Risk Has Disappeared

Breast cancer risk is not a single, universal number.

Risk may differ based on:

• Estrogen-only versus combined therapy
• Type of progestogen
• Duration of treatment
• Age at treatment initiation
• Baseline breast cancer risk
• Prior hormone exposure
• Family and personal medical history

The revised Bijuva label, for example, still includes breast cancer under contraindications and malignant neoplasms under warnings and precautions. It also retains age-specific and overall data from the WHI.

Removing breast cancer from the boxed warning changes how the information is prioritized. It does not remove the need for breast screening or informed discussion.

It Does Not Mean Cardiovascular Screening Is Unnecessary

Systemic estrogen, especially oral estrogen, can influence clotting and cardiovascular risk.

A clinician may consider factors such as:

• Smoking
• Blood pressure
• Cholesterol levels
• Insulin resistance or diabetes
• Obesity
• Previous blood clots
• Immobility
• Migraine history
• Family cardiovascular history
• Existing coronary or vascular disease

The route of estrogen administration may also matter. The Menopause Society notes that transdermal estrogen and lower doses may reduce the risk of venous thromboembolism and stroke compared with some oral regimens, although treatment still requires individualized evaluation.

It Does Not Make Hormone Therapy a Dementia Treatment

The FDA removed probable dementia language from the boxed warning and requested its removal from the broader labeling.

That should not be interpreted to mean hormone therapy is an approved treatment for Alzheimer’s disease or that women should begin therapy solely to prevent dementia.

Age, timing, formulation, and baseline health can affect neurologic outcomes. Hormone therapy should be prescribed for an appropriate clinical indication, not marketed as a guaranteed cognitive-protection strategy.

It Does Not Mean Systemic and Vaginal Estrogen Are the Same

Systemic hormone therapy circulates throughout the body and may be delivered through:

• Tablets
• Patches
• Gels
• Sprays
• Systemic vaginal rings

Local low-dose vaginal estrogen is primarily used to treat genitourinary syndrome of menopause, or GSM. Symptoms may include:

• Vaginal dryness
• Burning or irritation
• Pain during sex
• Urinary discomfort
• Urinary urgency
• Recurrent urinary tract symptoms

Products such as Estring produce substantially lower systemic estrogen exposure than standard systemic hormone therapy.

That difference is one reason medical organizations had questioned whether broad systemic warnings should appear unchanged on low-dose vaginal products.

Why Progesterone Still Matters for Women With a Uterus

Estrogen stimulates the lining of the uterus, called the endometrium.

When systemic estrogen is used without adequate endometrial protection in a woman who still has a uterus, it can increase the risk of endometrial hyperplasia and endometrial cancer.

A progestogen is generally added to systemic estrogen therapy to help protect the uterine lining.

This is why the FDA retained the endometrial cancer boxed warning for systemic estrogen-only products.

The progesterone plan may depend on:

• Whether the uterus is present
• Estrogen dose
• Treatment route
• Continuous versus cyclic therapy
• Bleeding pattern
• Medical history
• Tolerance and side effects

Any new, persistent, or unexpected postmenopausal bleeding should be evaluated rather than assumed to be a harmless hormone side effect.

Who May Benefit From Menopause Hormone Therapy?

Hormone therapy remains the most effective treatment for moderate to severe vasomotor symptoms, including hot flashes and night sweats.

Depending on the product and individual treatment plan, it may also help with:

• Menopause-related sleep disruption
• Vaginal dryness and discomfort
• Painful intercourse
• Genitourinary syndrome of menopause
• Prevention of bone loss and fractures
• Symptoms associated with early or premature menopause

Women with premature ovarian insufficiency or menopause occurring substantially earlier than average may have different treatment needs because prolonged estrogen deficiency can affect bone and other areas of health.

For many women, the central question is not simply, “Is hormone therapy safe?”

A more useful set of questions includes:

• What symptoms are being treated?
• How severe are they?
• How old is the patient?
• How long has it been since menopause began?
• Is the uterus present?
• Is local or systemic treatment needed?
• Which route best fits the patient’s risk profile?
• Are there contraindications?
• How will treatment be monitored?

What Should a Menopause Hormone Evaluation Include?

A responsible hormone therapy assessment should go beyond a short symptom checklist or a single hormone result.

Symptom and Menstrual History

The evaluation should review:

• Hot flashes and night sweats
• Sleep changes
• Vaginal and urinary symptoms
• Mood and cognitive concerns
• Cycle changes
• Last menstrual period
• Abnormal bleeding
• Symptom onset and severity

Medical and Family History

Important considerations may include:

• Breast, ovarian, uterine, or other cancers
• Blood clots
• Stroke or cardiovascular disease
• Liver or gallbladder disease
• Migraine
• Osteoporosis
• Thyroid disease
• Diabetes and metabolic risk
• Family history of cancer or clotting disorders

Current Medications and Supplements

Some medications and supplements can interact with hormone therapy or affect hormone metabolism.

A clinician should know about all prescription drugs, over-the-counter products, supplements, and previously used hormone treatments.

Blood Pressure, Screening, and Laboratory Data

Testing should be selected based on symptoms, age, medical history, and the proposed treatment.

Depending on the individual, an assessment may include:

• Blood pressure
• Lipid panel
• Blood glucose or hemoglobin A1c
• Liver function
• Thyroid markers
• Complete blood count
• Appropriate breast screening
• Bone density testing when indicated
• Additional hormone testing when it will change clinical decisions

Hormone levels can add context in selected cases, but treatment should not be based on a single “optimal” number while symptoms, medical history, and safety factors are ignored.

Follow-Up and Reassessment

Hormone therapy is not a prescription that should disappear into a chart for several years.

Follow-up should review:

• Symptom improvement
• Side effects
• Bleeding patterns
• Blood pressure
• Medication adherence
• New diagnoses or risk factors
• Whether the dose or route remains appropriate
• Whether continued treatment still matches the patient’s goals

FDA-Approved Hormones vs. Compounded Hormone Therapy

The FDA labeling change applies to FDA-approved drug products.

It does not automatically apply to compounded hormone preparations, which do not receive the same product-specific FDA review for safety, effectiveness, consistency, or labeling.

Some FDA-approved products contain hormones that are chemically identical to hormones produced by the human body, including estradiol and micronized progesterone.

The terms “bioidentical” and “compounded” are therefore not interchangeable.

Women considering hormone treatment should ask:

• Is this product FDA-approved or compounded?
• Why was this formulation selected?
• Is an FDA-approved option available?
• How consistent is the dosing?
• What monitoring is required?
• What evidence supports the proposed route and regimen?

You can learn more in our guide to bioidentical hormone replacement therapy for women.

What This FDA Decision Means for Menopause Care

For more than two decades, menopause hormone therapy conversations were frequently reduced to a binary message: hormones are dangerous, so women should avoid them whenever possible.

The evidence never fit comfortably into that simple conclusion.

Risk changes with age, treatment timing, health history, route, dose, formulation, and whether therapy is local or systemic.

The new FDA labels better reflect that complexity.

Women should not be frightened away from appropriate treatment by warnings that fail to distinguish between a 52-year-old with severe hot flashes and a 72-year-old beginning systemic therapy for chronic disease prevention.

At the same time, the pendulum should not swing toward treating hormone therapy as universally safe, anti-aging, or appropriate for every symptom.

Good menopause care lives between those extremes.

It combines current evidence with careful screening, shared decision-making, realistic expectations, and ongoing follow-up.

How 1st Optimal Approaches Menopause Hormone Care

At 1st Optimal, menopause care starts with the individual rather than a one-size-fits-all protocol.

A personalized assessment may include:

• Detailed symptom and health-history review
• Evaluation of cardiovascular and metabolic risk
• Review of breast and uterine health
• Comprehensive laboratory testing when clinically appropriate
• Discussion of estrogen, progesterone, testosterone, and nonhormonal options
• Selection of an appropriate dose and delivery method
• Follow-up testing and symptom reassessment
• Nutrition, strength training, sleep, gut health, and weight-management support

Hormone therapy may be one part of a broader plan. It should not be used to explain every symptom or replace investigation of thyroid dysfunction, sleep apnea, insulin resistance, nutrient deficiencies, gastrointestinal problems, or other conditions that can overlap with menopause.

Explore our perimenopause treatment options or review the 1st Optimal Women’s Hormone Program.

Frequently Asked Questions

Did the FDA say menopause hormone therapy is completely safe?

No. The FDA removed several risk statements from the boxed warning because the previous presentation did not adequately reflect differences in age, treatment timing, product type, and route. Contraindications and important warnings remain.

Did the FDA remove the breast cancer warning entirely?

Breast cancer language was removed from the boxed warning for the affected products. Breast cancer information and contraindications remain elsewhere in the prescribing information for systemic products.

Does the update apply to every hormone therapy product?

Not yet. The first approved group includes six products. The FDA reported that additional manufacturers had submitted proposed changes, so more labels may be updated after review.

Is vaginal estrogen safer than systemic estrogen?

Low-dose vaginal estrogen generally creates much lower systemic exposure and is intended mainly for vaginal and urinary symptoms. It should not be treated as identical to systemic oral, patch, gel, or spray therapy.

Do women with a uterus need progesterone?

Women using systemic estrogen who still have a uterus generally need adequate progestogen protection to reduce the risk of endometrial hyperplasia and cancer. The exact regimen should be determined by a qualified prescriber.

Can women start hormone therapy after age 60?

Age 60 is not an absolute prohibition. However, beginning systemic therapy after age 60 or more than 10 years after menopause may involve a less favorable risk-benefit balance. The decision requires individualized evaluation.

Should hormone therapy be used to prevent heart disease or dementia?

Hormone therapy should not be started solely as a guaranteed method of preventing heart disease or dementia. It should be used for an appropriate indication after evaluating the individual patient’s benefits and risks.

The Bottom Line

The FDA’s 2026 menopause hormone therapy labeling changes represent a major correction in how treatment risks are communicated.

Removing cardiovascular disease, breast cancer, and probable dementia from the boxed warning does not make hormone therapy risk-free. It does make room for a more accurate conversation.

For many healthy, symptomatic women younger than 60 or within 10 years of menopause, hormone therapy may offer meaningful relief and protection against bone loss when prescribed appropriately.

The right treatment depends on the woman, not just the warning label.

Book a free women’s health consultation with 1st Optimal to discuss your symptoms, health history, testing options, and whether a personalized menopause treatment plan may be appropriate.

Educational only, not medical advice. Hormone therapy requires evaluation and prescribing by a qualified healthcare professional.